ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2104

Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989

Theodore Pincus1, Tengfei Li2 and Juan Schmukler1, 1Rush University Medical Center, Chicago, IL, 2Rush, chicago, IL

Meeting: ACR Convergence 2025

Keywords: Health Services Research, Joint Structure, Osteoarthritis, pain, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2079–2105) Osteoarthritis – Clinical Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: A 1979 report by Huskisson, who developed the 0-10 pain visual analog scale (VAS) , entitled “Another look at osteoarthritis” indicated mean pain VAS scores of 5.3 in osteoarthritis RA (OA) and 5.25 in rheumatoid arthritis (RA) (Table). The earliest RAPID3 (routine assessment of patient index data) scores compiled in OA were 11.0 in 2009 and 11.7-13.6 in RA in 1989-2009. We analyzed subsequent databases from routine care which included pain and RAPID3 scores in patients with OA or RA, some of which also included 28 swollen joint counts (SJC) in patients with RA, presented to support credibility of the RA findings with recognized considerable improvement in inflammatory activity in RA, for comparisons of pain scores over time.

Methods: Available reports from routine care databases which included a 0-10 pain VAS in patients with RA or OA from 1979-2024, RAPID3 from 1989-2024, and 28 SJC in RA from 1985-2024 were compiled. Some reports presented mean and others median data; differences between median and mean values were less than 10% in reports which included both. Many reports were from a single investigator, and all but one of the databases were from the United States.

Results: Mean pain 0-10 VAS score reported in OA was 5.3 in 1979 and medians and means ranged from 3.9 to 7.0 through 2024, including 7.0 in 2024. Mean pain VAS in RA was 5.25 in 1979 and medians and means ranged from 2.5 to 5.5 through 2024, including 5.5 in 2024. Initial mean RAPID3 scores were 12.7 in OA and 13.6 in RA in 1989 (retrospectively computed according to group data); medians and means and ranged from 10.3 to 16.8 in OA and 6.2 to 13.3 in RA through 2024, including 14.0 in OA and 13.3 in RA in 2024. By contrast, mean SJC in RA was 12/28 in 1989 and ranged from 1.4 to 6.2 through 2024, including 1.4 in 2024 (data included to support credibility of non-SJC data).

Conclusion: Mean or median pain scores were similar in reports of OA and RA databases over 45 years from 1979 to 2024. Furthermore, RAPID3 in OA and RA were similar over 35 years from 1989 through 2024, whereas mean SJC in RA declined from 12 to 1.4 over this period. These findings document the effectiveness of modern anti-inflammatory therapy for RA, but suggest that the perception of status and illness experience for most OA and RA patients have improved minimally over decades. Important limitations of this review include comparisons of mean or median scores, although results were within 10% in databases which included both mean and median, and that all databases were from the USA other than one from Australia. These results are presented in part to encourage reporting of pain scores in OA and RA to recognize and account for possible differences from data presented in this abstract, toward better care and outcomes for OA and RA patients.

Supporting image 1Mean or median pain 0–10 visual analog scale (VAS) and 0-30 RAPID3 (routine assessment of patient index data) in routine care patients with osteoarthritis (OA) or rheumatoid arthritis (RA), and 28 swollen joint counts in RA from 1979 to 2024; initial and most recent values in each column are highlighted


Disclosures: T. Pincus: Medical history services, LLC, 8, 9, 10; T. Li: None; J. Schmukler: None.

To cite this abstract in AMA style:

Pincus T, Li T, Schmukler J. Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989 [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pain-0-10-visual-analog-scale-vas-and-rapid3-routine-assessment-of-patient-index-data-in-oa-and-ra-are-similar-in-2024-to-1979-and-1989/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pain-0-10-visual-analog-scale-vas-and-rapid3-routine-assessment-of-patient-index-data-in-oa-and-ra-are-similar-in-2024-to-1979-and-1989/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology